BioLife Solutions (BLFS) financial statements
BioLife Solutions reported revenue of $96M in fiscal 2025, up 31.4% a year over 9 years.
Net income was -$5M and the operating margin -17.3%, against -59.0% in 2016.
Free cash flow was $11M.
The diluted share count rose 285% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from BioLife Solutions's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $11M | $20M | $27M | $48M | $119M | $76M | $68M | $75M | $96M |
| Cost of revenue | $3M | $4M | $6M | $9M | — | — | — | $27M | $25M | $34M |
| Gross profit | $5M | $7M | $14M | $19M | — | — | — | $41M | $50M | $62M |
| Research and development | $2M | $1M | $1M | $3M | $7M | $12M | $9M | $6M | $5M | $8M |
| Selling, general and admin | $8M | $7M | $9M | $14M | $22M | $48M | $45M | $54M | $50M | $55M |
| Operating income | -$5M | -$1M | $4M | -$220,000 | -$6M | -$35M | -$6M | -$17M | -$4M | -$17M |
| Interest expense | $100,000 | $190,000 | $5,000 | $5,000 | — | — | — | — | — | — |
| Pre-tax income | — | -$3M | -$25M | -$3M | -$1M | -$29M | -$5M | -$12M | -$9M | -$12M |
| Income tax | $0 | $0 | — | -$2M | -$3M | -$20M | -$5M | -$64,000 | -$38,000 | $49,000 |
| Net income | -$7M | -$3M | -$25M | -$2M | $2M | -$9M | -$140M | -$68M | -$20M | -$5M |
| EPS (diluted) | -$0.54 | -$0.21 | $0.14 | -$0.09 | -$0.06 | -$0.23 | -$3.25 | -$1.55 | -$0.44 | -$0.10 |
| Diluted shares | 13M | 13M | 22M | 19M | 27M | 39M | 43M | 44M | 46M | 49M |
| Gross margin | 58.1% | 61.2% | 68.5% | 68.0% | — | — | — | 60.7% | 67.1% | 64.6% |
| Operating margin | -59.0% | -9.6% | 18.5% | -0.8% | -13.0% | -29.5% | -7.8% | -25.3% | -6.0% | -17.3% |
| Net margin | -83.6% | -22.8% | -126.7% | -6.1% | 4.1% | -7.5% | -183.4% | -100.0% | -27.0% | -4.8% |
Balance sheet
Fiscal years, from BioLife Solutions's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $1M | $7M | $31M | $6M | $90M | $70M | $64M | $50M | $109M | $120M |
| Receivables | $1M | $1M | $3M | $5M | $8M | $23M | $34M | $8M | $8M | $8M |
| Inventory | $2M | $2M | $4M | $11M | $12M | $28M | $35M | $27M | $29M | $30M |
| Total current assets | $5M | $10M | $38M | $24M | $115M | $126M | $138M | $121M | $149M | $137M |
| Property, plant and equipment | $1M | $1M | $1M | $6M | $10M | $18M | $24M | $6M | $6M | $15M |
| Goodwill | — | — | $0 | $34M | $58M | $58M | $225M | $212M | $209M | $209M |
| Total assets | $8M | $12M | $45M | $93M | $235M | $554M | $450M | $413M | $399M | $406M |
| Total current liabilities | $1M | $2M | $2M | $8M | $16M | $43M | $45M | $42M | $33M | $23M |
| Long-term debt | — | — | — | — | $655,000 | $6M | $24M | $18M | $5M | $0 |
| Total liabilities | $5M | $2M | $31M | $49M | $30M | $76M | $86M | $75M | $51M | $34M |
| Shareholders' equity | $3M | -$10M | $15M | $43M | $204M | $478M | $364M | $338M | $349M | $372M |
| Net debt | -$1M | -$7M | -$31M | -$6M | -$89M | -$63M | $6M | -$4M | -$76M | -$28M |
Cash flow
Fiscal years, from BioLife Solutions's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4M | $605,000 | $2M | $1M | $7M | -$5M | -$8M | -$12M | $8M | $20M |
| Capital spending | $1M | $144,000 | $500,000 | $675,000 | $2M | $8M | $10M | $6M | $3M | $9M |
| Free cash flow | -$6M | $461,000 | $2M | $538,000 | $5M | -$13M | -$19M | -$19M | $5M | $11M |
| Stock-based compensation | $776,994 | $1M | $2M | $3M | $6M | $14M | $25M | $33M | $31M | $23M |
| Free cash flow margin | -67.9% | 4.2% | 9.4% | 2.0% | 9.7% | -10.9% | -24.8% | -27.8% | 7.0% | 11.1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BLFS.
Open BLFS in InvestinglyQuestions
What was BioLife Solutions's revenue in 2025?
$96M in fiscal 2025, from its 10-K filing.
How much free cash flow does BioLife Solutions generate?
$11M in fiscal 2025 (operating cash flow minus capital spending).
From BioLife Solutions's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.